Compounds > zindoxifene
Page last updated: 2024-11-06

zindoxifene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

zindoxifene: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65645
CHEMBL ID32227
CHEBI ID35052
SCHEMBL ID424771
MeSH IDM0123752

Synonyms (30)

Synonym
NCI60_003032
d-16726
zindoxifene [inn]
1h-indol-5-ol, 2-(4-(acetyloxy)phenyl)-1-ethyl-3-methyl-, acetate (ester)
d 16726
2-(4-(acetyloxy)phenyl)-1-ethyl-3-methyl-1h-indol-5-ol acetate (ester)
1-ethyl-2-(p-hydroxyphenyl)-3-methylindol-5-ol diacetate (ester)
brn 4885631
zindoxifeno [spanish]
5-acetoxy-2-(4-acetoxyphenyl)-1-ethyl-3-methylindole
zindoxifenum [latin]
nsc341952
nsc-341952
86111-26-4
zindoxifene
CHEMBL32227
chebi:35052 ,
[4-(5-acetyloxy-1-ethyl-3-methylindol-2-yl)phenyl] acetate
1irs95m8dn ,
zindoxifenum
zindoxifeno
unii-1irs95m8dn
SCHEMBL424771
4-(5-(acetyloxy)-1-ethyl-3-methyl-1h-indol-2-yl)phenyl acetate
1h-indol-5-ol, 2-(4- (acetyloxy)phenyl)-1-ethyl-3-methyl-, acetate (ester)
DTXSID60235396
Q27116390
d 16726; nsc 341952
AKOS040745495
4-(5-acetoxy-1-ethyl-3-methyl-1h-indol-2-yl)phenyl acetate

Research Excerpts

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenylindole
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (21)

Assay IDTitleYearJournalArticle
AID130167Anti-uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 25 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID185784Percentage inhibition of uterotrophic activity at 25 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID140829Uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 625 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID130165Anti-uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 125 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID172748Change in DMBA-induced mammary carcinoma tumor area in rats at 1.8 mg dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID189076Number of DMBA-induced mammary carcinoma tumors in rats at 1.8 mg dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID140825Uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 125 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID140828Uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 5 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID140827Uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 25 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID130166Anti-uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 1 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID188571Formation of new DMBA-induced mammary carcinoma tumors in rats at 1.8 mg dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID172601Change in body weight of DMBA-induced mammary carcinoma tumor bearing rats at 1.8 mg dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID191769Percent unchanged DMBA-induced mammary carcinoma tumors in rats at 1.8 mg dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID71140Relative binding affinity for the calf uterine estrogen receptor.1988Journal of medicinal chemistry, Sep, Volume: 31, Issue:9
Platinum complexes with binding affinity for the estrogen receptor.
AID185782Percentage inhibition of uterotrophic activity at 125 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID130168Anti-uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 5 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID172758Change in DMBA-induced mammary carcinoma tumor area in rats at 1.8 mg dose; -75-6561984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID185779Percentage inhibition of uterotrophic activity at 1 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID189481Partial remission (%) of DMBA-induced mammary carcinoma tumors in rats at 1.8 mg dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID140826Uterotrophic activity in mice as uterus dry weight (mg)/body weight (g) *100 at 1 ug dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
AID188201Percent progressive DMBA-induced mammary carcinoma tumors in rats at 1.8 mg dose1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
2-Phenylindoles. Relationship between structure, estrogen receptor affinity, and mammary tumor inhibiting activity in the rat.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19908 (61.54)18.7374
1990's4 (30.77)18.2507
2000's1 (7.69)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (15.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (84.62%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
anastrozole
[no description available]		3.1110nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
letrozole
[no description available]		3.1110nitrile;
triazoles		antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor
9,10-dimethyl-1,2-benzanthracene
9,10-Dimethyl-1,2-benzanthracene: Polycyclic aromatic hydrocarbon found in tobacco smoke that is a potent carcinogen.. 7,12-dimethyltetraphene : A tetraphene having methyl substituents at the 7- and 12-positions. It is a potent carcinogen and is present in tobacco smoke.		1.9610ortho-fused polycyclic arene;
tetraphenes		carcinogenic agent
methylnitrosourea
Methylnitrosourea: A nitrosourea compound with alkylating, carcinogenic, and mutagenic properties.. N-methyl-N-nitrosourea : A member of the class of N-nitrosoureas that is urea in which one of the nitrogens is substituted by methyl and nitroso groups.		1.9610N-nitrosoureasalkylating agent;
carcinogenic agent;
mutagen;
teratogenic agent
raloxifene hydrochloride
Raloxifene Hydrochloride: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.. raloxifene hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.		3.1110hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
triazoles
Triazoles: Heterocyclic compounds containing a five-membered ring with two carbon atoms and three nitrogen atoms with the molecular formula C2H3N3.. triazoles : An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms.		3.11101,2,3-triazole
diethylstilbestrol
Diethylstilbestrol: A synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders. It was also used formerly as a growth promoter in animals. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. (Merck, 11th ed). diethylstilbestrol : An olefinic compound that is trans-hex-3-ene in which the hydrogens at positions 3 and 4 have been replaced by p-hydroxyphenyl groups.		2.3820olefinic compound;
polyphenol		antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen
tamoxifen citrate
[no description available]		1.9610citrate saltangiogenesis inhibitor;
anticoronaviral agent
tamoxifen
[no description available]		4.8360stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
toremifene
Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.		420aromatic ether;
organochlorine compound;
tertiary amine		antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
fosfestrol
fosfestrol: Rx of prostatic carcinoma; RN given refers to parent cpd with unspecified isomeric designation; structure		1.9710aryl phosphate
droloxifene
[no description available]		3.1110stilbenoid
idoxifene
idoxifene: structure given in first source		3.1110stilbenoid
tat 59
TAT 59: structure given in first source		3.1110aryl phosphate
acid phosphatase
Acid Phosphatase: An enzyme that catalyzes the conversion of an orthophosphoric monoester and water to an alcohol and orthophosphate. EC 3.1.3.2.		1.9710
ConditionIndicatedRelationship StrengthStudiesTrials
Experimental Mammary Neoplasms
[description not available]		02.6530
Breast Cancer
[description not available]		09.6160
Hormone-Dependent Neoplasms
[description not available]		02.8840
Breast Neoplasms
Tumors or cancer of the human BREAST.		04.6160
Menopause
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.		01.9610
Metastase
[description not available]		02.9210
Age-Related Osteoporosis
[description not available]		02.9210
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.9210
Osteoporosis
Reduction of bone mass without alteration in the composition of bone, leading to fractures. Primary osteoporosis can be of two major types: postmenopausal osteoporosis (OSTEOPOROSIS, POSTMENOPAUSAL) and age-related or senile osteoporosis.		02.9210
Adenocarcinoma, Basal Cell
[description not available]		02.3820
Cancer of Prostate
[description not available]		02.8940
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		02.3820
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.8940
Experimental Neoplasms
[description not available]		01.9710